Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Has Blockbuster Targets For Cosentyx In New Autoimmune Indications

Executive Summary

Next up for Cosentyx is psoriatic arthritis and ankylosing spondylitis. Novartis presented impressive long-term efficacy data at ACR in PsA and AS. Incoming CEO and Chief Medical Officer Vas Narasimhan said the company sees a blockbuster opportunity and is exploring the anti-TNF naïve market in AS.

Advertisement

Related Content

Celgene Admits It Screwed Up Otezla Estimates; Investors Lose Confidence
Lilly Math: Subtracting Employees And Animal Health Equals Pharma Growth
Revamped Novartis In Good Shape At 3Q Ahead Of CEO Succession
FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx
PIPELINE WATCH – Five Approvals, Two Launches And A Breakthrough
Novartis adds another Cosentyx approval with FDA nod

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099855

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel